PHASE-II TRIAL OF ORAL VP-16-213 (ETOPOSIDE) IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER

被引：6
|
作者：
CRIVELLARI, D
VERONESI, A
MAGRI, MD
TIRELLI, U
COMORETTO, R
BARZAN, L
CARUSO, G
CARBONE, A
GRIGOLETTO, E
机构：
[1] CTR RIFERIMENTO ONCOL, DIV MED ONCOL, I-33081 AVIANO, ITALY
[2] CTR RIFERIMENTO ONCOL, DIV RADIOTHERAPY, I-33081 AVIANO, ITALY
[3] CTR RIFERIMENTO ONCOL, DIV PATHOL, I-33081 AVIANO, ITALY
[4] GEN HOSP, DIV OTOLARYNGOL, PORDENONE, ITALY
来源：
TUMORI JOURNAL | 1985年 / 71卷 / 05期
关键词：
D O I：
10.1177/030089168507100514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We tested VP16-213 in 16 patients with advanced head and neck cancer after conventional treatment. VP-16-213 was administered orally at the dosage of 100 mg/mq for 5 consecutive days every 3 weeks. No patient achieved an objective response. Toxicity was mild. VP-16-213 given at this dose and schedule revealed no activity in pretreated patients with head and neck cancer.
引用
收藏
页码：499 / 500
页数：2
相关论文
共 50 条
  • [21] PHASE-II TRIAL OF MITOXANTRONE IN HEAD AND NECK-CANCER
    AAPRO, MS
    ALBERTS, DS
    INVESTIGATIONAL NEW DRUGS, 1984, 2 (03) : 329 - 330
  • [22] PHASE-II EVALUATION OF PALA IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER
    CREAGAN, ET
    NICHOLS, WC
    OFALLON, JR
    CANCER TREATMENT REPORTS, 1981, 65 (9-10): : 827 - 829
  • [23] PHASE-II TRIAL OF MITOGUAZONE IN PATIENTS WITH RECURRENT HEAD AND NECK-CANCER
    CONINX, P
    NASCA, S
    JEZEKOVA, D
    ROELANDT, H
    MOREL, M
    LEGROS, M
    CATTAN, A
    BULLETIN DU CANCER, 1985, 72 (02) : 153 - 154
  • [24] ORAL VP-16-213 IN TRANSITIONAL CELL-CARCINOMA OF THE BLADDER - A PHASE-II STUDY
    PANDURO, J
    HANSEN, M
    HANSEN, HH
    CANCER TREATMENT REPORTS, 1981, 65 (7-8): : 703 - 704
  • [25] PHASE-II TRIAL OF N-METHYLFORMAMIDE IN ADVANCED HEAD AND NECK-CANCER
    VOGEL, WC
    FORASTIERE, AA
    NATALE, RB
    TAKASUGI, BJ
    SCHNUR, G
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (02) : 203 - 206
  • [26] PHASE-II TRIAL OF VP16-213 IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    CLERICO, M
    BERTETTO, O
    DONGIOVANNI, V
    CALCIATI, A
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (05): : 577 - 577
  • [27] PHASE-II EVALUATION OF VP-16-213 IN PATIENTS WITH ADVANCED BREAST-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    VAUGHN, CB
    PANETTIERE, F
    THIGPEN, T
    BOTTOMLEY, R
    HOOGSTRATEN, B
    SAMAL, B
    CANCER TREATMENT REPORTS, 1981, 65 (5-6): : 443 - 445
  • [28] HEXAMETHYLMELAMINE IN ADVANCED HEAD AND NECK-CANCER - A PHASE-II STUDY
    GADELMAWLA, N
    MACDONALD, JS
    KHALED, H
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1984, 7 (03): : 205 - 208
  • [29] A PHASE-II STUDY OF PIRITREXIM IN PATIENTS WITH ADVANCED SQUAMOUS HEAD AND NECK-CANCER
    UEN, WC
    HUANG, AT
    MENNEL, R
    JONES, SE
    SPAULDING, MB
    KILLION, K
    HAVLIN, K
    KEEGAN, P
    CLENDENINN, NJ
    CANCER, 1992, 69 (04) : 1008 - 1011
  • [30] PHASE-II TRIAL OF AZIRIDINYLBENZOQUINONE (AZQ) IN HEAD AND NECK-CANCER
    FORASTIERE, AA
    CRAIN, SM
    CALLAHAN, K
    VANECHO, D
    MATTOX, D
    THANT, M
    VONHOFF, DD
    WIERNIK, PH
    CANCER TREATMENT REPORTS, 1982, 66 (12): : 2097 - 2098
12345